Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...

Based on the one-year price targets offered by 2 analysts, the average target price for Dolby Laboratories Inc (NYSE:DLB) is $100 with a high estimate of $100 and a low estimate of $100.

Three of XMLV's underlying holdings with notable upside to their analyst target prices are Dolby Laboratories Inc (Symbol: DLB), CACI International Inc (Symbol: CACI), and Federated Hermes Inc ...

DLB is a common cause of dementia ... This research is part of an international collaboration led by Dr. Daniel Ferreira from Karolinska Institutet with Dr. Kejal Kantarci at Mayo Clinic.

today provided an update on its neflamapimod development program in dementia with Lewy bodies (DLB) as part of an oral presentation at the 8 th International Lewy Body Dementia Conference (ILBDC ...